Spots Global Cancer Trial Database for Study of Anlotinib in Patients With Primary Malignant Bone Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Anlotinib in Patients With Primary Malignant Bone Tumors
Official Title: A Single-Arm, Open-Label, Multicenter Clinical Trial With Anlotinib Hydrochloride Capsule for Primary Malignant Bone Tumors With Recurrence and Distant Metastases
Study ID: NCT03527888
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Jishuitan Hospital, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Shanghai No.6 People's Hospital, Shanghai, Shanghai, China
The First Affiliated Hospital of the Air Force Medical University, Xi'an, Shanxi, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact Details
Name: Yang Yao
Affiliation: Shanghai 6th People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
